公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2014 | A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region | Soon S.-S.; Lopes G.; Lim H.-Y.; Wong-Rieger D.; Bahri S.; Hickinbotham L.; Jha A.; BOR-SHENG KO ; MacDonell D.; Pwu J.R.-F.; Shih R.; Sirachainan E.; Suh D.-C.; Wale J.; Zhang X.; Wee H.-L. | Orphanet Journal of Rare Diseases | 5 | 4 | |
2010 | Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma | Yeo W.; PEI-JER CHEN ; Furuse J.; Han K.-H.; CHIUN HSU ; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. | BMC Cancer | 4 | 4 | |
2020 | Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial | Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU | JAMA Oncology | 697 | 646 | |
2020 | Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies | Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU ; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. | Liver Cancer | 12 | 10 | |
2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
2010 | Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion | PEI-JER CHEN ; Furuse J.; Han K.-H.; CHIUN HSU ; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. | Liver International | 37 | 34 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2013 | Roles of cancer registries in enhancing oncology drug access in the asia-pacific region | Soon S.-S.; Lim H.-Y.; Lopes G.; Ahn J.; Hu M.; Ibrahim H.M.; Jha A.; BOR-SHENG KO ; Lee P.W.; MacDonell D.; Sirachainan E.; Wee H.-L. | Asian Pacific Journal of Cancer Prevention | 3 | 1 |